|
UBIAD1 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.62536650805123E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.45417011765403E-12 |
| Normal-vs-Stage2 |
4.36189999997172E-06 |
| Normal-vs-Stage3 |
1.0325074129014E-14 |
| Normal-vs-Stage4 |
1.63902225125412E-12 |
| Stage1-vs-Stage2 |
2.357400E-01 |
| Stage1-vs-Stage3 |
3.281500E-02 |
| Stage1-vs-Stage4 |
1.595610E-03 |
| Stage2-vs-Stage3 |
9.783100E-03 |
| Stage2-vs-Stage4 |
1.117240E-03 |
| Stage3-vs-Stage4 |
3.097600E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
8.88178419700125E-16 |
| Normal-vs-AfricanAmerican |
9.40009999950142E-07 |
| Normal-vs-Asian |
4.38599999652567E-08 |
| Caucasian-vs-AfricanAmerican |
9.389200E-01 |
| Caucasian-vs-Asian |
3.297600E-01 |
| AfricanAmerican-vs-Asian |
5.496200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
2.02526884152121E-12 |
| Normal-vs-Female |
1.62836411021772E-12 |
| Male-vs-Female |
6.778400E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
7.05047131788206E-12 |
| Normal-vs-Age(41-60Yrs) |
1.09356967925578E-13 |
| Normal-vs-Age(61-80Yrs) |
1.68876024275733E-12 |
| Normal-vs-Age(81-100Yrs) |
1.516600E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
3.507200E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
2.141000E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
9.226000E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
6.748200E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
8.412000E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
6.928600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
6.771500E-04 |
| Classical-VS-Follicular |
3.934800E-01 |
| Classical-VS-Other |
4.252800E-01 |
| Classical-VS-Normal |
1.80955250783654E-12 |
| Tall-VS-Follicular |
2.917900E-02 |
| Tall-VS-Other |
6.692800E-01 |
| Tall-VS-Normal |
5.28022070511724E-13 |
| Follicular-VS-Other |
6.999200E-01 |
| Follicular-VS-Normal |
1.85549997588907E-09 |
| Other-VS-Normal |
1.616720E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
3.14293036041136E-12 |
| Normal-vs-N1 |
2.52464715799761E-13 |
| N0-vs-N1 |
9.540800E-03 |
|
|
